Health Care & Life Sciences » Biotechnology | Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
69,649.00
139,925.00
136,562.00
233,662.00
249,655.00
202,818
Other Current Assets
618.00
1,122.00
1,865.00
4,028.00
4,487.00
4,530
Total Current Assets
70,267.00
141,047.00
138,427.00
237,690.00
254,142.00
220,175
Net Property, Plant & Equipment
132.00
240.00
3,816.00
7,857.00
31,932.00
60,525
Total Investments and Advances
-
18,275.00
13,808.00
-
-
-
Other Assets
59.00
1,523.00
3,076.00
2,707.00
4,202.00
4,344
Total Assets
70,458.00
161,085.00
159,127.00
248,254.00
290,276.00
285,044
Accounts Payable
1,442.00
-
-
5,610.00
6,245.00
Income Tax Payable
-
-
1,721.00
-
-
Other Current Liabilities
2,040.00
8,887.00
15,395.00
13,761.00
18,939.00
Total Current Liabilities
3,482.00
8,887.00
17,116.00
19,371.00
25,184.00
Long-Term Debt
-
124,156.00
123,236.00
123,539.00
123,845.00
Other Liabilities
-
-
-
-
5,648.00
Total Liabilities
3,482.00
133,043.00
140,352.00
142,910.00
154,677.00
Common Equity (Total)
66,976.00
28,042.00
18,775.00
105,344.00
135,599.00
Total Shareholders' Equity
66,976.00
28,042.00
18,775.00
105,344.00
135,599.00
Total Equity
66,976.00
28,042.00
18,775.00
105,344.00
135,599.00
Liabilities & Shareholders' Equity
70,458.00
161,085.00
159,127.00
248,254.00
290,276.00

About Aerie Pharmaceuticals

View Profile
Address
4301 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.aeriepharma.com
Updated 07/08/2019
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.